Opus Genetics vs Praxis Precision Medicines
IRD and PRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRD and PRAX compare
Praxis Precision Medicines is the larger company, worth 27 times as much as Opus Genetics ($9.7B against $359M).
Praxis Precision Medicines scores higher on the StockData Score (7 against 5 for Opus Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRD | PRAX |
|---|---|---|
| Size and price | ||
| Market cap | $359M | $9.7B |
| Share price | $4.31 | $346.21 |
| Change, 1 year | 119% | 106% |
| Change, 5 years | 18.4% | 23.6% |
| Beta (5Y) | 0.98 | 1.66 |
| Employees | 27 | 168 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 45.3× | – |
| P/B | 9.3× | 7.7× (better) |
| FCF yield | – | −3.3% |
| Fair value | $0.739 | – |
| Margin of safety | −483% | – |
| Growth | ||
| Revenue growth (TTM) | −45.9% | – |
| Profitability | ||
| Operating margin | −778% | – |
| Net margin | −1727% | – |
| Return on equity | −616% | −44.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −217.5× | – |
| Current ratio | 9.65 | 14.53 (better) |
| Altman Z-score | −1.73 | 108.60 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −0.68% | – |
| Shareholder yield | −0.68% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 72.8% | 121% |
| Held by insiders | 37.6% | 0.72% |
| Insider net buying, 12 months | −$19.4M | −$3.6M (better) |
| Short interest, % of float | 20.9% | 15.2% |
Go deeper
- IRD stock overview
- IRD income statement
- IRD valuation and score
- PRAX stock overview
- PRAX income statement
- PRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.